<DOC>
	<DOCNO>NCT03087071</DOCNO>
	<brief_summary>The goal clinical research study learn panitumumab alone combination trametinib help control advance colorectal cancer . The safety drug also study .</brief_summary>
	<brief_title>Panitumumab Combination With Trametinib Cetuximab-Refractory Stage IV Colorectal Cancer</brief_title>
	<detailed_description>Study Groups : If participant find eligible take part study , participant assign 1 3 group base result genetic test do screening . - If participant Group 1 3 , participant receive panitumumab alone . - If participant Group 2 , participant receive receive panitumumab trametinib . If participant Group 1 3 disease appear get bad , participant may able cross-over group 2 begin receive panitumumab trametinib combination therapy . Study Drug Administration : Each study cycle 14 day . Participant receive panitumumab vein 60-90 minute Day 1 cycle . After first dose , participant check side effect 60 minute dose . If intolerable side effect occur , participant 's next dose last 30 minute participant check side effect 30 minute afterward . If participant Group 2 , participant take trametinib mouth 1 time every day . Participant take trametinib tablet morning time day , least 1 hour 2 hour meal . Participant swallow capsule 1 cup ( 8 ounce ) water . Participant swallow capsule whole ( without chew ) , one right . At end study cycle participant stop take study drug , participant return unused trametinib capsule study nurse . Length Study : Participant may continue receive study drug ( ) long doctor think participant 's best interest . Participant longer able receive study drug ( ) disease get bad , intolerable side effect occur , participant unable follow study direction . Study Visits : On Day 1 every cycle : - Blood ( 6 tablespoon ) draw routine biomarker test . - If doctor think need , participant eye exam . - Participant physical exam ( Cycles 1-4 , every even-numbered cycle ) - Participant EKG ( Cycles 1-4 , every even-numbered cycle ) . - Participant either ECHO MUGA scan ( Cycles 2 , 4 , 10 , every 6 cycle ) On Day 10 Cycle 2 , doctor think need , participant eye exam . On Day 10 Cycle 4 every 4 cycle ( Cycles 8 , 12 , 16 , ) : - Participant CT participant 's chest CT/MRI participant 's abdomen pelvis . - If doctor think need , participant eye exam . End Treatment Visit : Within 28-35 day participant 's last dose study drug , participant end-of-treatment visit . The following test procedure perform : - Participant physical exam . - Blood ( 5 tablespoon ) draw routine biomarker test . - Participant EKG either ECHO MUGA scan . - Participant CT scan participant 's chest CT scan MRI participant 's abdomen pelvis . - If doctor think need , participant eye exam . - If participant become pregnant , blood ( 1 teaspoon ) collect pregnancy test . Long-Term Follow-Up : Every 3 month end treatment visit , member study staff contact participant ask participant . This contact take place either regularly schedule clinic visit phone . Each phone call last 10 minute . This investigational study . Panitumumab FDA approve commercially available treatment colorectal cancer . Trametinib FDA approve commercially available treatment melanoma . The combination drug consider investigational treatment advance colorectal cancer.The study doctor explain study drug design work . Up 84 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically cytologically confirm colorectal adenocarcinoma , metastatic disease document diagnostic imaging study 2 . Progression within 6 month fluoropyrimidine , irinotecan , oxaliplatin . For oxaliplatinbased therapy , failure therapy also include patient progress within 12 month adjuvant therapy patient oxaliplatin discontinue secondary toxicity allergic reaction . Patients known history Gilbert 's disease receive irinotecan patient intolerant irinotecan fluoropyrimidine eligible . 3 . Confirmed wildtype status KRAS exon 2 , 3 , 4 ; NRAS exons 2 , 3 , 4 ; BRAF , standard care test tumor specimen . Tissue use testing may collect prior treatment cetuximab . 4 . Patient must already test available result mutation status KRAS/NRAS/BRAF EGFR circulate tumor DNA within 10 week prior start study therapy . 5 . Previous treatment cetuximab evidence clinical benefit , define complete response , partial response , prolong stable disease 16 week treatment without radiographic progression , assess treat physician document medical record . This treatment may occur point patient 's clinical course treatment metastatic colorectal cancer . 6 . Ultimate progression previous treatment cetuximab , document clinical progression . Patients discontinue cetuximab reason , decline performance status , hypersensitivity , adverse effect therapy , eligible . 7 . All prior treatment related toxicity must CTCAE ( Version 4.0 ) &lt; /= Grade 1 ( except alopecia ) 8 . Radiographically measurable disease present per RECIST 1.1 9 . Age &gt; /= 18 year 10 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 11 . Blood count perform within 3 week prior start study therapy must absolute neutrophil count &gt; /= 1,500/mm3 , platelet &gt; /= 100,000/mm3 , hemoglobin &gt; /= 9 g/dL 12 . Liver function test perform within 3 week prior start study therapy must total bilirubin &lt; /= 1.5 x upper limit normal ( ULN ) , alanine aminotransferase aspartate aminotransferase &lt; /= 2.5 x ULN ( &lt; /= 5 x ULN liver metastasis present ) , albumin &gt; /= 2.5 g/dL 13 . Serum creatinine perform within 3 week prior start study therapy must &lt; /= 1.5 x ULN , calculate creatinine clearance ( use CockcroftGault formula ) &gt; /= 50 mL/minute . 14 . PT/INR PTT perform within 3 week prior start study therapy must &lt; /= 1.5 x ULN 15 . Left Ventricular Ejection fraction ( LVEF ) &gt; /= LLN ECHO MUGA within 3 week prior start study therapy . 16 . Women childbearing potential must negative serum pregnancy test within 14 day prior randomization must agree use effective contraception throughout treatment period 4 month last dose study treatment . 17 . Ability sign inform consent form . Informed consent form study must sign prior performance studyspecific procedure initiation study therapy . 18 . Ability swallow retain oral medication , clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel . 19 . In cohort 1 , must EGFR S492R ectodomain mutation detect circulate tumor DNA plasma collect progression prior cetuximab . May concomitant mutation KRAS , NRAS , BRAF , least 5fold high allele frequency prevalent EGFR mutation prevalent KRAS/NRAS/BRAF mutation . 20 . In cohort 2 , must one mutation find KRAS exon 2 , 3 , 4 ; NRAS exon 2 , 3 , 4 ; BRAF codon 600 . May concomitant EGFR ectodomain mutation , prevalent EGFR ectodomain mutation 5fold high allele frequency prevalent KRAS/NRAS/BRAF mutation . 21 . In cohort 3 , must EGFR ectodomain mutation mutation KRAS , NRAS , BRAF . 22 . Patients must consent MD Anderson ATTACC protocol prior inclusion . 1 . Past treatment MEK ERK inhibitor panitumumab 2 . Previous retreatment cetuximab follow progression initial course cetuximab therapy 3 . Known untreated brain metastasis brain metastasis treat within 3 month prior enrollment trial 4 . Symptomatic untreated leptomeningeal brain metastasis spinal cord compression . 5 . History interstitial lung disease pneumonitis 6 . History malignancy within 3 year , except adequately treat carcinoma situ cervix nonmelanoma skin cancer and/or subject indolent second malignancy eligible . 7 . Prior treatment within 21 day first dose study drug chemotherapy , immunotherapy , biologic therapy , vaccine therapy , investigational treatment , failure recover adverse effect prior therapy administer 4 week prior Study Day 1 . All toxicity prior therapy must &lt; /= Grade 1 ( &lt; /= Grade 2 alopecia peripheral neuropathy ) . Prior systemic treatment adjuvant setting allow . 8 . Any major surgery , extensive radiotherapy , chemotherapy delay toxicity , biologic therapy , immunotherapy within 21 day prior randomization and/or daily weekly chemotherapy without potential delayed toxicity within 14 day prior randomization . 9 . Impaired cardiac function clinically significant cardiac disease , define : ) Left ventricular ejection fraction &lt; low limit normal ( LLN ) multiple gated acquisition scan ( MUGA ) echocardiogram ; b ) Congenital long QT syndrome family history unexpected sudden cardiac death ; c ) QTc correct Bazett 's formula ( QTcB ) &gt; /= 480 ms. ; ) History evidence current clinically significant uncontrolled arrhythmia . Note subject atrial fibrillation control &gt; 30 day prior dose eligible ; 10 . Continuation criterion : e ) History acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month prior randomization ; f ) History evidence current &gt; /= Class II congestive heart failure define New York Heart Association ( NYHA ) ; g ) Treatment refractory hypertension define blood pressure systolic &gt; 140 mmHg and/or diastolic &gt; 90 mm Hg control antihypertensive therapy ; h ) Patients intracardiac defibrillator . 11 . Any serious and/or unstable preexist medical disorder ( aside malignancy exception ) , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent , compliance study procedure . 12 . History retinal vein occlusion ( RVO ) 13 . Pregnant breastfeeding , plan become pregnant within 6 month end treatment . 14 . History organ allograft history immunodeficiency . 15 . Inability unwillingness comply study and/or followup requirement 16 . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug , excipients dimethyl sulfoxide ( DMSO ) . 17 . Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) infection . Subjects laboratory evidence clear HBV HCV infection permit . 18 . Current use prohibit medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Colorectal adenocarcinoma</keyword>
	<keyword>EGFR S492R ectodomain mutation circulate free tumor DNA</keyword>
	<keyword>Detectable KRAS NRAS mutation exon 2 , 3 , 4 ; BRAF codon 600 mutation circulate free tumor DNA</keyword>
	<keyword>No detectable mutation circulate free tumor DNA</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Vectibix</keyword>
	<keyword>Trametinib</keyword>
	<keyword>GSK1120212</keyword>
</DOC>